Do analysts recommend COYA or VIRI?

Coya Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 260.78%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, BDTX or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics N/A N/A $22.37M -$0.77 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is BDTX or VIRI more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Virios Therapeutics N/A -130.33% -115.00%

Do analysts rate FTLF or VIRI?

FitLife Brands presently has a consensus price target of $21.50, suggesting a potential upside of 109.76%. Given FitLife Brands' stronger consensus rating and higher possible upside, research analysts clearly believe FitLife Brands is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ALDX or VIRI?

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 261.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ALDX or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is ALDX or VIRI more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Virios Therapeutics N/A -130.33% -115.00%

Do analysts prefer ONCY or VIRI?

Oncolytics Biotech currently has a consensus price target of $8.50, suggesting a potential upside of 946.54%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Oncolytics Biotech is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ONCY or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is ONCY or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% Virios Therapeutics N/A -130.33% -115.00%

Virios Therapeutics (VIRI) Competitors

$1.50 -0.04 (-2.60%)

As of 07/24/2026

Compare

VIRI vs. COYA, BDTX, FTLF, ALDX, and ONCY

Should you buy Virios Therapeutics stock or one of its competitors? MarketBeat compares Virios Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virios Therapeutics include Coya Therapeutics (COYA), Black Diamond Therapeutics (BDTX), FitLife Brands (FTLF), Aldeyra Therapeutics (ALDX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Virios Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Virios Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	12.56	-$21.23M	-$1.15	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coya Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

In the previous week, Coya Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Coya Therapeutics and 0 mentions for Virios Therapeutics. Coya Therapeutics' average media sentiment score of 0.87 beat Virios Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
Virios Therapeutics	Neutral

Virios Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Virios Therapeutics	N/A	-130.33%	-115.00%

Coya Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 260.78%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Coya Therapeutics beats Virios Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Black Diamond Therapeutics presently has a consensus target price of $9.83, indicating a potential upside of 458.71%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Black Diamond Therapeutics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Virios Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.46 beat Virios Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Virios Therapeutics	Neutral

Black Diamond Therapeutics' return on equity of -30.18% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Virios Therapeutics	N/A	-130.33%	-115.00%

Virios Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.77	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Black Diamond Therapeutics beats Virios Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, FitLife Brands had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for FitLife Brands and 0 mentions for Virios Therapeutics. FitLife Brands' average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Very Positive
Virios Therapeutics	Neutral

FitLife Brands has a net margin of 6.64% compared to Virios Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Virios Therapeutics	N/A	-130.33%	-115.00%

FitLife Brands presently has a consensus price target of $21.50, suggesting a potential upside of 109.76%. Given FitLife Brands' stronger consensus rating and higher possible upside, research analysts clearly believe FitLife Brands is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 61.7% of FitLife Brands shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

FitLife Brands has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$90.85M	1.06	$6.33M	$0.60	17.08
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

FitLife Brands has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Summary

FitLife Brands beats Virios Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 261.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 0 mentions for Virios Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.44 beat Virios Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Virios Therapeutics	Neutral

Aldeyra Therapeutics' return on equity of -57.34% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Virios Therapeutics	N/A	-130.33%	-115.00%

Aldeyra Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Summary

Aldeyra Therapeutics beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Oncolytics Biotech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for Virios Therapeutics. Oncolytics Biotech's average media sentiment score of 0.94 beat Virios Therapeutics' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Virios Therapeutics	Neutral

Virios Therapeutics' return on equity of -130.33% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Virios Therapeutics	N/A	-130.33%	-115.00%

Oncolytics Biotech currently has a consensus price target of $8.50, suggesting a potential upside of 946.54%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Oncolytics Biotech is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oncolytics Biotech and Virios Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.89M	$975.11M	$6.86B	$12.25B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-5.56	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.01	89.03
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	7.50	8.47	10.28	6.07
Net Income	-$5.30M	-$2.70M	$3.60B	$331.99M
7 Day Performance	8.70%	-2.29%	-1.27%	-0.63%
1 Month Performance	-0.66%	-3.97%	-0.37%	-2.00%
1 Year Performance	-68.29%	27.39%	18.30%	13.62%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.50 -2.6%	N/A	-68.0%	$28.89M	N/A	N/A	5
COYA Coya Therapeutics	2.5274 of 5 stars	$4.55 +2.5%	$15.33 +237.0%	-36.8%	$104.15M	$7.95M	N/A	6	News Coverage
BDTX Black Diamond Therapeutics	3.6521 of 5 stars	$1.87 +3.3%	$9.83 +425.8%	-43.6%	$103.72M	N/A	N/A	90	Positive News
FTLF FitLife Brands	4.425 of 5 stars	$10.58 -3.8%	$21.50 +103.2%	-22.8%	$103.30M	$90.85M	17.52	20	Positive News Gap Up
ALDX Aldeyra Therapeutics	3.6145 of 5 stars	$1.75 +2.9%	$5.50 +214.3%	-72.1%	$102.55M	N/A	N/A	10	Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. COYA, BDTX, FTLF, ALDX, and ONCY

How does Virios Therapeutics compare to Coya Therapeutics?

Summary

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Summary

How does Virios Therapeutics compare to FitLife Brands?

Summary

How does Virios Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Virios Therapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. COYA, BDTX, FTLF, ALDX, and ONCY

How does Virios Therapeutics compare to Coya Therapeutics?

Which has preferable valuation and earnings, COYA or VIRI?

Do institutionals and insiders have more ownership in COYA or VIRI?

Which has more volatility and risk, COYA or VIRI?

Does the media prefer COYA or VIRI?

Is COYA or VIRI more profitable?

Do analysts recommend COYA or VIRI?

Summary

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Do analysts rate BDTX or VIRI?

Do insiders & institutionals have more ownership in BDTX or VIRI?

Which has more risk & volatility, BDTX or VIRI?

Does the media favor BDTX or VIRI?

Is BDTX or VIRI more profitable?

Which has higher valuation and earnings, BDTX or VIRI?

Summary

How does Virios Therapeutics compare to FitLife Brands?

Does the media prefer FTLF or VIRI?

Is FTLF or VIRI more profitable?

Do analysts rate FTLF or VIRI?

Do institutionals and insiders hold more shares of FTLF or VIRI?

Which has better valuation & earnings, FTLF or VIRI?

Which has more volatility & risk, FTLF or VIRI?

Summary

How does Virios Therapeutics compare to Aldeyra Therapeutics?

Do institutionals & insiders hold more shares of ALDX or VIRI?

Do analysts rate ALDX or VIRI?

Which has higher earnings and valuation, ALDX or VIRI?

Does the media prefer ALDX or VIRI?

Is ALDX or VIRI more profitable?

Which has more risk and volatility, ALDX or VIRI?

Summary

How does Virios Therapeutics compare to Oncolytics Biotech?

Which has more volatility & risk, ONCY or VIRI?

Which has stronger earnings and valuation, ONCY or VIRI?

Do insiders & institutionals hold more shares of ONCY or VIRI?

Does the media favor ONCY or VIRI?

Is ONCY or VIRI more profitable?

Do analysts prefer ONCY or VIRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools